There is no widely available cure for HIV. As of 2024, approximately 40.8 million people worldwide are living with the virus, and the standard treatment remains daily or long-acting antiretroviral therapy (ART), which suppresses the virus but does not eliminate it. A handful of individuals have been cured through highly specialized stem cell transplants, and several experimental strategies are in clinical trials, but none are ready for general use. Here’s what the science actually looks like right now.
Why HIV Is So Hard to Cure
The core obstacle is something called the latent reservoir. Very early during infection, HIV inserts its genetic code into the DNA of resting immune cells, particularly a type of white blood cell called memory CD4+ T cells. These cells aren’t actively producing virus, so the immune system can’t detect them and ART can’t reach them. They sit quietly in the blood, lymph nodes, gut lining, and even the central nervous system, essentially hiding in plain sight.
When someone stops taking ART, these dormant cells can reactivate at any time and begin producing new copies of the virus. This is why viral levels typically rebound within weeks of stopping treatment. A true cure would need to either flush out and destroy every last one of these hidden cells or permanently prevent them from ever waking up.
Two Definitions of “Cured”
Researchers work with two distinct goals. A sterilizing cure means completely eliminating every trace of HIV from the body, the way you’d think of curing an infection. A functional cure is more like long-term remission: the virus may still exist in tiny amounts, but the person’s immune system controls it indefinitely without medication. Both would mean no daily pills and no risk of progression to AIDS, but only a sterilizing cure would mean the virus is truly gone.
The People Who Have Been Cured
To date, roughly seven people have achieved what appears to be a lasting cure, all through stem cell transplants they received as treatment for blood cancers like leukemia or lymphoma, not for HIV itself. The transplants replaced their immune systems with donor cells, and in most cases those donor cells carried a rare genetic mutation called CCR5-delta32. People born with two copies of this mutation lack the surface receptor HIV typically uses to enter cells, making them naturally resistant to infection.
The most famous case is Timothy Ray Brown, known for years as “the Berlin patient,” who received a transplant from a donor with two copies of the mutation in 2007 and remained HIV-free until his death from cancer in 2020. The “London patient,” treated similarly, has also shown sustained remission. More recently, a patient known as B2 demonstrated that even a transplant from a donor with only one copy of the mutation can lead to durable remission lasting years, suggesting that complete genetic resistance to HIV isn’t strictly necessary. What seems to matter most is that the transplant process itself drastically reduces the viral reservoir.
None of this translates to a practical treatment for the tens of millions living with HIV. Stem cell transplants carry a significant risk of death, require a matched donor, and involve intensive chemotherapy or radiation to destroy the existing immune system first. They’re a last resort for cancer, not a viable HIV strategy.
Gene Editing With CRISPR
One of the most closely watched approaches uses CRISPR gene-editing technology to cut HIV’s genetic code directly out of infected cells. A therapy called EBT-101 delivers CRISPR components into the body through a harmless virus, aiming to snip out integrated HIV DNA wherever it’s hiding.
Early results have been sobering. In the first human trial, five participants received a single infusion of EBT-101. Three of them later stopped ART, and all three saw their virus rebound, requiring them to restart medication. One participant did manage to stay suppressed for 16 weeks after stopping treatment, notably longer than the typical rebound window, which hinted that the therapy was doing something. But it wasn’t enough. The company behind EBT-101 is now testing a higher dose and exploring better delivery methods to get the editing tools into more of the cells that harbor latent virus.
Antibody-Based Treatments
Another promising line of research involves broadly neutralizing antibodies, lab-made versions of the powerful antibodies that a small percentage of people with HIV produce naturally. These antibodies can recognize and neutralize a wide range of HIV strains. In clinical trials, combinations of these antibodies have kept viral levels suppressed for months after participants stopped taking ART, something standard treatment alone cannot do.
The challenge is that HIV mutates rapidly, and resistant strains often break through even when multiple antibodies are combined. In trials testing three antibodies at once, the breakthrough rate has still been unacceptably high. A more recent approach pairs two antibodies with a long-acting capsid inhibitor (a drug that blocks HIV from assembling new copies of itself). In a phase 2 study, this combination maintained viral suppression in 18 of 20 participants over 26 weeks. That’s encouraging, but the follow-up period is short, and it’s not yet clear whether this represents a path toward remission or simply a new form of ongoing treatment.
The “Shock and Kill” Strategy
This approach tries to solve the reservoir problem head-on: force dormant HIV out of hiding (“shock”) so the immune system or another therapy can destroy the newly exposed cells (“kill”). Researchers have tested a range of drugs designed to wake up sleeping virus, including compounds originally developed for cancer treatment.
Several of these agents have successfully nudged latent HIV into producing detectable signs of activity in clinical trials. For example, certain drugs originally used in cancer therapy increased measurable HIV activity in participants who had been fully suppressed on ART. But in every trial so far, these increases have been too small and too inconsistent to meaningfully shrink the reservoir. The “shock” part works to a degree. The “kill” part hasn’t kept pace. Without a reliable way to eliminate the reactivated cells, waking the virus up accomplishes little on its own.
What Treatment Looks Like Today
While a cure remains out of reach, modern ART has transformed HIV from a fatal diagnosis into a manageable chronic condition. Globally, more than 77% of people living with HIV were receiving antiretroviral therapy in 2024, and 73% had achieved suppressed viral loads.
The practical significance of viral suppression goes beyond personal health. The CDC states that a person living with HIV who maintains an undetectable viral load has zero risk of transmitting the virus to sexual partners. This principle, known as U=U (Undetectable equals Untransmittable), is backed by large studies tracking thousands of couples over years without a single linked transmission. For many people, effective treatment already delivers much of what a functional cure would offer: a normal lifespan, good health, and no risk of passing the virus to others. The key difference is that it requires ongoing medication.
Global Progress and Gaps
The international community set a goal to end AIDS as a public health threat by 2030, aiming to reduce new infections and AIDS-related deaths by 90% compared to 2010 levels. In eastern and southern Africa, the hardest-hit region, new infections and deaths have each dropped by nearly 60% since 2010. Countries that reached 90% treatment coverage by 2024 saw new infections fall by 72%, putting them on track to meet the 2030 target.
Progress has been uneven, though. New infections have plateaued or increased in Asia, eastern Europe, central Asia, Latin America, and the Middle East. Children, adolescent girls, young women, and key populations including men who have sex with men, transgender people, people who inject drugs, and sex workers continue to face lower treatment coverage and higher infection rates. A cure would be transformative for these communities especially, where access to daily medication is often the barrier that determines outcomes.
Where Things Stand
No pill, injection, or therapy available today can cure HIV for the general population. The small number of people cured through stem cell transplants prove it’s biologically possible, and several experimental approaches, from gene editing to antibody combinations to reservoir-flushing drugs, are inching closer to replicating that result without the extreme risks of a transplant. Each strategy has shown flashes of promise in early trials alongside clear limitations. The most realistic near-term advances will likely come from combining multiple approaches: pairing something that shrinks the reservoir with something that prevents rebound. For now, consistent antiretroviral therapy remains the most effective tool, capable of keeping the virus undetectable, preventing transmission, and allowing a full, healthy life.